UFC featherweight title contender Chad Mendes has been handed a two year suspension on Wednesday by the United States Anti-Doping Agency (USADA). This comes on the heels of a failed out-of-competition test from May relating to a growth hormone drug. Mendes (17-4 MMA, 8-4 UFC), contended for the featherweight championship on three different occasions. He fell short twice against Jose Aldo then faced Conor McGregor in an interim title bout, again coming up short. His most recent bout was a knockout loss to Frankie Edgar at The Ultimate Fighter 22 finale.
Mendes was tested out-of-competition on May 17 and tested positive for a growth-hormone releasing hexapeptide, also known as GHRP-6. That substance is classified under the category of peptide hormones, growth factors, related substances and mimetics. According to the World Anti-Doping Agency (WADA), to which USADA is a signatory, the substance is banned year-round.
Under USADA rules, the standard sanction for a violation for this kind of substance is a two year suspension. His suspension will be retroactive to June 10, which is when Mendes received his provisional suspension pending resolution of the case. He would be eligible to return to the Octagon in June of 2018. Also under the policy, Mendes has also been “disqualified from all competitive results obtained on and subsequent to May 17, 2016, the date of sample collection, including forfeiture of any title, ranking, purse or other compensation.”
USADA’s statement does not tell if Mendes, 31, has accepted the punishment. The full USADA statement can be read on their website.
Information from MMAJunkie.com was used in this piece.